Description: HCW Biologics Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation and age-related diseases. The company is involved in developing HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. It is also developing HCW9218 as an injectable immunotherapeutic for patients with pancreatic, breast, ovarian, colorectal, and prostate cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata. The company was incorporated in 2018 and is headquartered in Miramar, Florida.
Home Page: www.hcwbiologics.com
HCWB Technical Analysis
2929 North Commerce Parkway
Miramar,
FL
33025
United States
Phone:
954 842 2024
Officers
| Name | Title |
|---|---|
| Dr. Hing C. Wong Ph.D. | Founder, CEO, Director & Sec. |
| Ms. Rebecca Byam CPA, M.B.A. | Chief Financial Officer |
| Dr. Peter Rhode Ph.D. | Chief Scientific Officer & VP of Clinical Operations |
| Ms. Nicole Valdivieso Esq. | VP of Legal Affairs |
| Ms. Raquel Diaz M.S. | Director of HR |
| Mr. Lee D. Flowers | Sr. VP of Bus. Devel. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.728 |
| Price-to-Sales TTM: | 13.3337 |
| IPO Date: | 2021-07-20 |
| Fiscal Year End: | December |
| Full Time Employees: | 44 |